Heart failure hospitalization — Research & Evidence

Q: What does the research say about Heart failure hospitalization?

The scientific consensus on Heart failure hospitalization is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for Heart failure hospitalization?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What the evidence says about Heart failure hospitalization

Synthesized from 192 evidence-backed clinical questions linked to this topic — 68 supporting the intervention, 42 against the intervention, 15 still contested.

Does vericiguat vs placebo affect Cardiovascular Death or Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

vericiguat vs placebo · Cardiovascular Death or Heart Failure Hospitalization

1 studies (5,050 patients, 1 RCTs) provide moderate-certainty evidence for benefit of vericiguat for Composite of cardiovascular death or first heart-failure hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction.

Moderate evidence for1 RCT · 5,050 patients

Does vericiguat vs placebo affect Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

vericiguat vs placebo · Heart Failure Hospitalization

1 studies (5,050 patients, 1 RCTs) provide moderate-certainty evidence for benefit of vericiguat for Total heart-failure hospitalizations (first and recurrent) in Worsening Chronic Heart Failure with Reduced Ejection Fraction.

Moderate evidence for1 RCT · 5,050 patients

Does vericiguat vs placebo affect All-Cause Mortality in Worsening Chronic Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

vericiguat vs placebo · All-Cause Mortality

1 studies (5,050 patients, 1 RCTs) provide moderate-certainty evidence for benefit of vericiguat for All-cause mortality in Worsening Chronic Heart Failure with Reduced Ejection Fraction.

Moderate evidence for1 RCT · 5,050 patients

Does sacubitril/valsartan vs enalapril affect NT-proBNP change from baseline in Acute Decompensated Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

sacubitril/valsartan vs enalapril · NT-proBNP change from baseline

1 studies (881 patients, 1 RCTs) provide moderate-certainty evidence for benefit of sacubitril/valsartan for Time-averaged proportional change in NT-proBNP (weeks 4-8) in Acute Decompensated Heart Failure with Reduced Ejection Fraction.

Moderate evidence for1 RCT · 881 patients

Does sacubitril/valsartan vs enalapril affect Heart failure rehospitalization in Acute Decompensated Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

sacubitril/valsartan vs enalapril · Heart failure rehospitalization

1 studies (881 patients, 1 RCTs) provide moderate-certainty evidence for benefit of sacubitril/valsartan for Rehospitalization for heart failure in Acute Decompensated Heart Failure with Reduced Ejection Fraction.

Moderate evidence for1 RCT · 881 patients

Actively debated

Does mineralocorticoid receptor antagonists vs placebo improve outcomes in Heart failure?

Insufficient~ Mixed results

mineralocorticoid receptor antagonists vs placebo

31 studies (721,214 patients) provide insufficient evidence with mixed findings regarding mineralocorticoid receptor antagonists for the outcome in Heart failure.

Equivocal31 studies · 721,214 patients

Does mra vs placebo improve outcomes in Heart failure?

Insufficient~ Mixed results

mra vs placebo

6 studies (38,091 patients) provide insufficient evidence with mixed findings regarding mra for the outcome in Heart failure.

What does the research say about Heart failure hospitalization?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Clinical questions in Heart failure hospitalization

Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.

Does vericiguat vs placebo affect Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

vericiguat vs placebo · Heart Failure Hospitalization

1 RCT · 5,050 patients· 1 estimates

Does vericiguat vs placebo affect Cardiovascular Death or Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?

Moderate Certainty+ Favors benefit

vericiguat vs placebo · Cardiovascular Death or Heart Failure Hospitalization

Journal clubs discussing Heart failure hospitalization

Recent sessions

tets 1

Cornell - Precision Medicine — Mon, Aug 10, 5:45 PM EDT

Tri.Fr: The Heart of the Matter

OPCI Journal Club — Fri, Aug 7, 12:00 PM EDT

Cardiac intense unit demo

Cornell - Precision Medicine — Thu, Jul 23, 2:15 PM EDT

Demo

Synapse Team — Fri, Jun 19, 3:15 PM EDT — 3 attended

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on Heart failure hospitalization

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF

Journal of the American Heart Association — Fudim M — Dec 2020

Contemporary management of acute heart failure in the emergency department and the potential impact of early diuretic therapy on outcomes

Emergency Medicine Australasia — Phipps G — Sep 2023

Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study

EP Europace — Meier V — Oct 2025

Heart Failure and Incident Late‐Life Depression

Journal of the American Geriatrics Society — Luijendijk H — Jun 2010

The relationship between three eGFR formulas and hospitalization for heart failure in 54 486 individuals with type 2 diabetes

Stay current on Heart failure hospitalization

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Featured authors in Heart failure hospitalization

Journal Club takes on Heart failure hospitalization

Evidence brief: Heart failure hospitalization

Heart failure hospitalization (also known as ADHF, acute heart failure, HF admission). Acute decompensated HF and hospitalization outcomes

Synapse tracks 5 specific clinical questions in Heart failure hospitalization, each synthesized independently from its own trial evidence. They include: "Does vericiguat vs placebo affect Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?"; "Does vericiguat vs placebo affect Cardiovascular Death or Heart Failure Hospitalization in Worsening Chronic Heart Failure with Reduced Ejection Fraction?"; "Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction?"; "Does sglt2 inhibitors vs placebo improve Cardiovascular Mortality in Heart failure?"; "Does exenatide vs placebo improve All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent?".

As of 2026-08-15, the scientific consensus on Heart failure hospitalization is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on Heart failure hospitalization. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/heart-failure-hospitalization.

Deterministic synthesis from Synapse's enriched corpus — 298 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for Heart failure hospitalization?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest Heart failure hospitalization research

Explore every Heart failure hospitalization paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search Heart failure hospitalization papers